Nowe oblicze gruźlicy

• Authors: Augustynowicz-Kopeć Ewa

Title variants

EN

The new face of tuberculosis

• Languages of publication: PL

Abstracts

PL

Artykuł przedstawia historię gruźlicy lekoopornej oraz sytuację epidemiologiczną gruźlicy na świecie, a szczególnie w Polsce. Wyjaśniony został mechanizm powstawania oporności prątków gruźlicy na leki oraz przyczyny wzrostu zapadalności na gruźlicę w ostatnich latach. Scharakteryzowano programy i instytucje monitorujące występowanie gruźlicy na poziomie globalnym oraz znaczenie zalecanych przez Międzynarodowy Komitet ds. Standaryzacji Badań Molekularnych w Gruźlicy technik molekularnych dla identyfikacji Mycobacterium tuberculosis Beijing. Polska przez pięć ostatnich lat była partnerem w europejskim projekcie badawczym TB-PANET, który był realizowany przez 28 krajów i dotyczył badań molekularnych nad prątkami gruźlicy.

EN

The article presents the history of drug-resistant tuberculosis and epidemiological situation of tuberculosis in the world, especially in Poland. A mechanism of acquired drug resistance in M. tuberculosis is clarified and the increasing incidence of tuberculosis is explained. The most important global programmes and efforts to end tuberculosis and identify Mycobacterium tuberculosis Beijing are characterized. Molecular methods are recognized as an international standard in the world-wide fight against tuberculosis. During last five years, Poland was one of twenty eight countries which participated in the European research project TB-PLANET.

Keywords

PL

gruźlica,; walka z gruźlicą,; gruźlica wielolekoporna

EN

tuberculosis,; fight against tuberculosis, multi-drug-resistant tuberculosis

• Publisher: Uniwersytet Medyczny w Poznaniu
• Journal: Acta Medicorum Polonorum
• Year: 2018
• Volume: 8
• Issue: 1
• Pages: 23-36
• Document type: review article

Dates

printed

2018-08-18

Contributors

author

Augustynowicz-Kopeć Ewa

• Instytut Gruźlicy i Chorób Płuc w Warszawie

References

• Augustynowicz-Kopeć E., Zwolska Z., Gruźlica w Europie i w Polsce – nowe rodziny molekularne i nowe wzory oporności, „Przegl. Epidemiol.” 2008, 62, s. 113-121.
• Augustynowicz-Kopeć E., Zwolska Z., Zastosowanie badań molekularnych w diagnostyce gruźlicy, [w:] Choroby wewnętrzne. Stan wiedzy na 2017, red. A. Szczeklik, Kraków 2017.
• 3. Casali N. i wsp., Microevolution of extensively drug-resistant tuberculosis in Russia, “Genome Res.” 2012, 22, s. 735-745.
• Centers for Disease Control and Prevention. Revised definition of extensively drug-resistant tuberculosis, “MMWR”, 2006, 55, s. 1176.
• Cohn D. L., Bustero F., Raviglione M. C., Drug resistant in tuberculosis: review of the worldwide situaation and WHO/IUATLD global surveillance project, “Clin. Infect. Dis.” 1997, 24 (Suppl. 1), s. S121-S130.
• DeJesus Mai i wsp., Comprehensive Essentiality Analysis of the Mycobacterium tuberculosis Genome via Saturating Transposon Mutagenesis, “MBio.” 2017, 8(1), s. 2133-16.
• Diaz R., Kremer P., de Hass E. i wsp., Molecular epidemiology of tuberculosis in Cuba outside of Havana July 1994-June 1995 utility of spoligotyping versus IS6110 restriction fragment length polymorphism, “Int. J. Tuberc Lung Dis.” 1998, 2, s. 743-750.
• Dormans J., Burger M., Aguilar D. F. i wsp., Correlation of virulence, lung pathology, bacterial load and delayed type hypersensitivity responses after infection with different Mycobacterium tuberculosis genotypes in a BALB/c mouse model, “Clin. Exp. Immunol.” 2004, 137, s. 460-468.
• Dudnyk A., Chesov D., Lange C., Mission impossible: the End TB strategy, “Int J Tuberc Lung Dis.” 2018, 22(2), s. 121-122.
• Dudnik A., Rzhepishevska O., Rogach K. i wsp., Multidrug-resistant tuberculosis in Ukraine at a time of military conflict, “Int. J. Tuberc Lung Dis.” 2015, 19(4), s. 492-496.
• Gandhi N.R., Moll A., Sturm A.W. i wsp., Extensively drug-resistant tuberculosis as a cause of death in patients coinfected with tuberculosis and HIV in a rural area of South Africa, “Lancet” 2006, 368, s. 1575–1580.
• Grange J. M., Laszlo A., Serodiagnostic tests for tuberculosis: a need for assessment of their operational predictive accuracy and susceptibility, “Bull. World Health Organ.” 1990, 68, s. 571-576.
• Gruft H., Johnson R., Claflin R. i wsp., Phage-typing and drug –resistance patterns as tools in mycobacterial epidemiology, “Am. Rev. Respir. Dis.” 1984, 130, s. 96-97.
• Gruźlica i choroby układu oddechowego w Polsce w 2016 r., red. Maria Korzeniewska-Koseła, Instytut Gruźlicy i Chorób Płuc, Warszawa 2017.
• Gutierrez M.C., Brisse S., Brosch R., Fabre M., Omaïs B., Marmiesse M. i wsp., Ancient origin and gene mosaicism of the progenitor of Mycobacterium tuberculosis, “PloS Pathog, PLoS“, 2005, 1(1), s. 5-19.
• Herzog H., History of tuberculosis, ”Respiration” 1998, 65(1), s. 5-15.
• Huyen M. N. i wsp., Tuberculosis relapse in Vietnam is significantly associated with Mycobacterium tuberculosis Beijing genotype infections, “J Infect Dis” 2013, 15;207(10), s. 1516-24.
• Jajou R. i wsp., Epidemiological links between tuberculosis cases identified twice as efficiently by whole genome sequencing than conventional molecular typing: A population-based study, “PLoS One” 2018,13(4).
• Jong E. i wsp., Two cases of Mycobacterium microti-induced culture-negative tuberculosis, “J Clin Microbiol.” 2009; 47(9), 3038-40.
• Liu H.C. i wsp., Molecular Typing Characteristic and Drug Susceptibility Analysis of Mycobacterium tuberculosis Isolates from Zigong, China, “Biomed Res Int.” 2016; 2016: 6790985.
• Liu Yi i wsp., The study on the association between Beijing genotype family and drug susceptibility phenotypes of Mycobacterium tuberculosis in Beijing, “Scientific Reports” 2017, 7(1).
• Marttila H., Soini H., Eerola E. i wsp., A Ser315Thr substitution in Kat G is predominant ingenetically heterogenous multidrug-resistant Mycobacterium tuberculosis isolates originating from St.Petersburg area in Russia, “Antimicrob. Agents Chemother.” 1998, 42, s. 2443-2445.
• Nunn P., Wright A., WHO Task Force Meeting on XDR TB, Geneva 2008.
• O'Garra A. i wsp., The Immune Response in Tuberculosis, “Annual Review of Immunology” 2013, 31, s. 475-527.
• Panteix G. i wsp., Pulmonary tuberculosis due to Mycobacterium microti: a study of six recent cases in France, “J. Med. Microbiol.”, 2010, 59, s. 984–989.
• Pavlenko E. i wsp., Alarming levels of multidrug-resistant tuberculosis in Ukraine: results from the first national survey, “Int J Tuberc Lung Dis.”, 2018, 22(2), s. 197-205.
• Pitondo-Silva A. i wsp., Comparison of three molecular typing methods to assess genetic diversity for Mycobacterium tuberculosis, “J Microbiol Methods”, 2013 Apr, 93(1), s. 42-8.
• Rad M., Bifani P., Martin C. i wsp., Mutation in putative mutator genes of mycobacterium tuberculosis strains of W-Beijing family, “Emerg. Infect. Dis.” 2003, 9, s. 828-845.
• Rattan A., Kalia A., Ahmad N., Multidrug-resistant mycobacterium tuberculosis: molecular perspectives, “Emerg. Infect. Dis.” 1998, 4(2), s. 195–210.
• Sreevatsan S., Pan X., Stockbauer K.E., Connell N.D., Kreiswirth B.N., Whittam T.S. i wsp., Restricted structural gene polymorphism in the Mycobacterium tuberculosis complex indicates evolutionarily recent global dissemination, “Proc Natl Acad Sci USA”, 1997, 94, s. 9869-9874.
• Soolingen D., Hoogenboezem T., de Haas E. W. i wsp., A novel pathogenic taxon of Mycobacterium tuberculosis complex. Canetti: characterization of an exceptional isolate from Africa, “Int. J. Syst. Bacterial.” 1997, 47, s. 1236-1245.
• Thwaites G., Caws M., Hong Chau T., Relationship between Mycobacterial tuberculosis genotype and the clinical phenotype of pulmonary and meningeal tuberculosis, “J. Clin. Microbiol.” 2008, 46, 4, s.1363-1368.
• Warren R., Hauman J., Beyers N. i wsp., Unexpectedly high strain diversity of Mycobacterium tuberculosis in a high-incidence community, “S. Afr. Med.” 1996, 86, s. 45-9.
• WHO Global TB Report 2016, Geneva, Switzerland 2017.
• WHO Percentage of previously treated TB cases with MDR-TB. WHO Global TB Report, Geneva 2016.